Site-Specific Antibody Conjugation Service
CD BioGlyco provides an integrated solution of Antibody Glycoengineering. Our advanced Glycoengineering Platform and high-quality site-specific antibody conjugation services will fully meet your needs. We have the confidence to be your essential research assistant in the field of glycobiology.
Antibody-drug conjugates are a promising class of tumor-targeted therapeutic drugs. The cell selectivity of monoclonal antibodies can selectively destroy malignant cells while sparing healthy tissue. The key to the construction of this conjugate is the covalent linker between the two components. The combination of macromolecular biology and small-molecule chemistry is the key to the success of antibody-drug conjugates.
To improve conventional conjugation methods to generate these heterogeneous products, various site-specific methods have been developed. These methods conjugate functional small molecules to specific sites in antibody molecules, including cysteine, glutamine, unnatural amino acids, short peptide tags, and glycans. The resulting antibody-drug conjugates showed high homogeneity and potent antitumor activity both in vitro and in vivo.
Chemically defined antibody conjugates can be synthesized in commercially relevant yields and generate antibody-drug conjugates with improved properties relative to heteroconjugates formed by non-specific chemical modification. Site-specific antibody-drug conjugates produced by enzymatic modification also show improved stability and pharmacokinetics.
Fig.1 Strategies to functionalise cysteine-engineered antibodies to generate homogeneous antibody-drug conjugates. (Walsh, et al., 2021)
CD BioGlyco provides advanced technologies for the site-specific conjugation of IgG with Alexa Fluor 488, Alexa Fluor 555, Alexa Fluor 647, biotin, DFO, or azide. The technologies sre implemented using Fc glycan remodeling and a click chemistry approach.
In addition, we provide you with custom antibody conjugate services if our existing site-specific antibody conjugation services do not meet your specific needs. Our custom conjugate services are efficient and quality-assured.
Our site-specific antibody conjugation with azide service includes the following two parts:
Our workflow is designed to guide your project from initial concept to a high-quality, fully characterized conjugate. Each stage is supported by our team of expert scientists, ensuring clear communication and meticulous execution.
After understanding your specific research goals, target molecule, and desired payload, we will evaluate the physicochemical properties of the antibody and payload and, based on this, recommend the optimal site-specific conjugation strategy to achieve your project objectives.
Antibodies for conjugation are prepared according to the research plan. If genetic engineering is selected, our team will develop recombinant antibodies with the desired site-specific reactive handles. For other approaches, we ensure the antibodies are purified and maintained under optimal buffer conditions for subsequent conjugation steps.
To prepare payloads for conjugation, we synthesize linker-payload molecules or purchase and activate your selected payload. Our expert chemists ensure that the linker is stable and the payload is functionalized with appropriate reactive groups for efficient and clean reaction with the designated binding site on the antibody.
This is the core step in bioconjugation. The prepared antibody is conjugated to the activated linker-payload under carefully controlled reaction conditions optimized for high yield and specificity.
The final conjugate is purified to remove any unconjugated payload, unreacted antibody, and other byproducts. We then perform a comprehensive series of quality control analyses, including mass spectrometry (MS) and size exclusion chromatography (SEC).
Journal: Pharmaceuticals
IF: 4.8
Published: 2021
Results: This study uses native MS and ion mobility techniques to characterize a homogeneous site-specific antibody-drug conjugates, T-GlyCLICK-DM1, made via glycan remodeling and click chemistry. SEC-nMS tracked conjugation stages, confirming the end product's homogeneity. Thermal degradation studies via SEC-nMS identified aggregates and fragments but no drug deconjugation. Ion mobility-based collision-induced unfolding (CIU) showed drug conjugation boosted stability. These methods effectively monitor antibody-drug conjugates synthesis, degradation, and conformational changes for next-gen homogeneous antibody-drug conjugates characterization.
Fig.2 Schematic overview of the bioconjugation protocol. (Deslignière, et al., 2021)
With extensive experience, rich industry knowledge, and an advanced Glycoengineering Platform, CD BioGlyco is committed to making a difference in your program of site-specific antibody conjugation to develop a favorable candidate. Our world-class scientists and technicians will cooperate closely with our clients to accelerate the project. For more detailed information and quote, please feel free to contact us for deep communication.
To fully support your research and development journey, CD BioGlyco offers a suite of complementary services and products that can be seamlessly integrated with our site-specific antibody conjugation service.
Glycosylation Site-specific ADC Development
As a full-service provider, we handle the entire ADC development process, from target identification and antibody selection to conjugation, in vitro assays, and pre-clinical analysis.
Antibody Glycoengineering Servivices
Our specialized services in glycobiology assist with glycoengineering your antibody to create novel site-specific conjugation sites or to optimize its function and stability.
Advanced Glycoprotein Analysis Services
We offer a range of advanced analytical services to fully characterize your antibody and its conjugate, including sequencing, post-translational modification analysis, and functional assays.
References
